Evidence-Based Oncology > The American Society of Clinical Oncology Annual Meeting, 2015

Evidence-Based Oncology - The American Society of Clinical Oncology Annual Meeting, 2015

July 10, 2015 – Surabhi Dangi-Garimella, PhD
Two posters summarized the safety of nivolumab in lung cancer and in glioblastoma, at the ASCO annual meeting.
July 10, 2015 – Surabhi Dangi-Garimella, PhD
Basket and umbrella studies as well as adaptive enrichment design strategies represent novel approaches to testing targeted therapeutics in oncology, and a session at ASCO's annual meeting discussed the nuts and bolts of these design strategies.
July 10, 2015 – Anita T. Shaffer
A landmark clinical trial that will channel patients into treatment arms based on molecular abnormalities rather than cancer type aims to simultaneously test the efficacy of more than 20 drugs.
July 13, 2015 – Surabhi Dangi-Garimella, PhD
The American Journal of Managed Care invited healthcare experts to discuss the challenges associated with managing and paying for newer and more expensive agents in oncology, during the Oncology Stakeholders Summit.
July 13, 2015 – Surabhi Dangi-Garimella, PhD
During the Oncology Stakeholder's Summit 2015 hosted by AJMC, healthcare experts discuss the value of introducing palliative and end-of-life care discussions early in oncology care.
July 13, 2015 – Surabhi Dangi-Garimella, PhD
A poster presented at the 2015 annual meeting of the American Society of Clinical Oncology shared encouraging phase 3 survival data from the RECOURSE trial, after evaluating specific geographic subgroups.
July 15, 2015 – Surabhi Dangi-Garimella, PhD
At the annual meeting of the American Society of Clinical Oncology, Robin Zon, MD, discussed the growing administrative burdens in oncology practice with the movement towards value-based payment.
July 15, 2015 – Surabhi Dangi-Garimella, PhD
A very popular session on the "value" of cancer care during the annual meeting of the American Society of Clinical Oncology (ASCO) brought together a patient representative, an oncologist, an ASCO representative, and a payer.
July 15, 2015 – Surabhi Dangi-Garimella, PhD
During the session "Health Services Research and Quality of Care" at the annual meeting of the American Society of Clinical Oncology, oncologists discussed factors that influence clinical trial participation and the cost of cancer care.
July 16, 2015 – Surabhi Dangi-Garimella, PhD
A late-breaking abstract session early at the annual meeting of the American Society of Clinical Oncology presented datd for nivolumab in the treatment of hepatocellular carcinoma, non-squamous cell non-small cell lung cancer, and for tumors harboring mismatch repair deficiency.
July 16, 2015 – Surabhi Dangi-Garimella, PhD
Immuno-oncology continues to deliver results in oncology, as seen from results presented at the annual meeting of the American Society of Clinical Oncology. The combination of nivolumab and ipilimumab significantly improved survival in melanoma, while elotozumab showed encouraging results in relapsed refractory multiple myeloma.
July 16, 2015 – Surabhi Dangi-Garimella, PhD
At the annual meeting of the American Society of Clinical Oncology in Chicago, physicians introduced some new lymphoma treatments as they described their personal experience with using them during the session, "Incorporating Novel Agents Into Lymphoma Therapy: Value in Everyday Practice."
July 16, 2015 – Jason M. Broderick
A presscast held prior to the annual meeting of the American Society of Clincal Oncology presented interim results from the phase 3 ELOQUENT-2 trial. Adding elotuzumab to lenalidomide and dexamethasone reduced the risk of disease progression by 30% in patients with relapsed-refractory multiple myeloma.
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.